Fayez Sarofim & Co Has $609.17 Million Holdings in Abbott Laboratories $ABT

Fayez Sarofim & Co decreased its holdings in Abbott Laboratories (NYSE:ABT) by 0.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,515,964 shares of the healthcare product maker’s stock after selling 6,333 shares during the quarter. Abbott Laboratories accounts for about 1.4% of Fayez Sarofim & Co’s portfolio, making the stock its 22nd largest holding. Fayez Sarofim & Co’s holdings in Abbott Laboratories were worth $609,165,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories during the third quarter worth approximately $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories in the third quarter valued at approximately $31,000. Anfield Capital Management LLC grew its position in Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares in the last quarter. Delos Wealth Advisors LLC bought a new position in Abbott Laboratories during the 2nd quarter worth $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new position in Abbott Laboratories in the 3rd quarter valued at $33,000. Institutional investors own 75.18% of the company’s stock.

Insiders Place Their Bets

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the sale, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 over the last 90 days. Insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Weiss Ratings lowered Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Raymond James Financial dropped their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Piper Sandler reduced their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Citigroup decreased their target price on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a report on Wednesday, March 11th. Finally, Daiwa Securities Group cut their price target on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $107.99 on Monday. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $139.06. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The stock’s 50-day simple moving average is $114.58 and its 200 day simple moving average is $123.80. The firm has a market capitalization of $187.66 billion, a PE ratio of 29.03, a price-to-earnings-growth ratio of 1.72 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.